KINETA INC - KANT STOCK NEWS

TuHURA Biosciences (NASDAQ:HURA) announced two abstracts accepted for poster presentation at the 2025 AACR Annual Meeting in Chicago. The presentations will showcase:

1. Initial results from a Phase 1 study of KVA12123, an anti-VISTA antibody, both as monotherapy and in combination with pembrolizumab for advanced solid tumors, presented by Kineta's CSO.

2. Mechanistic insights into IFx-Hu2.0 therapy responses in patients with prior anti-PD-1 therapy failure in advanced melanoma, presented by Moffitt Cancer Center scientists.

The company also referenced its previously announced definitive agreement from December 11, 2024, to acquire Kineta, including rights to KVA12123, through a merger expected to close in Q2 2025, subject to funding and other closing conditions.

TuHURA Biosciences (NASDAQ:HURA) has entered into a definitive merger agreement to acquire Kineta, Inc. (OTC PINK:KANT), gaining rights to Kineta's novel KVA12123 antibody. The acquisition adds a Phase 2 novel checkpoint inhibitor to TuHURA's pipeline, with plans for a Phase 2a/b trial in mutated NPM1 AML in 2025.

KVA12123 is a VISTA-blocking immunotherapy administered as a monoclonal antibody infusion every two weeks. It has completed enrollment in its monotherapy arm, demonstrating safety at 1000mg dose level, and is finishing combination therapy trials with KEYTRUDA®. The transaction, following a $5 million exclusivity fee paid in July 2024, is expected to close in Q1 2025.

Kineta (OTC Pink: KANT) provided updates on its VISTA101 Phase 1/2 clinical trial for KVA12123, an anti-VISTA monoclonal antibody. The trial evaluates KVA12123 both as monotherapy and in combination with Merck's KEYTRUDA® in advanced solid tumors. Key findings include: successful clearance of all six monotherapy dose levels and second of four combination cohorts, no dose limiting toxicities, and favorable safety profiles. In monotherapy, 13 of 19 evaluable patients showed stable disease. The combination therapy demonstrated promising results, including a partial response with 54% tumor reduction and a confirmed complete response in non-target lesions.

Kineta announced the completion of enrollment in the monotherapy cohorts of its Phase 1 VISTA-101 clinical trial evaluating KVA12123, a novel VISTA blocking immunotherapy, in patients with advanced solid tumors. The trial enrolled patients in 6-dose cohorts ranging from 3mg to 1000mg every two weeks, with no dose limiting toxicities or cytokine related adverse events observed.

The study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). Initial results reported earlier this year showed partial response and stable disease in combination cohorts and durable stable disease in monotherapy cohorts. Kineta aims to complete full enrollment before year-end and will present additional scientific data in 2024 at an upcoming scientific meeting.

Kineta, a clinical-stage biotech firm, announced its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, held November 6-10, 2024, in Houston, Texas and virtually. The poster, presented by Dr. Jason Henry on November 8, 2024, will reveal new clinical data from an ongoing Phase 1/2 trial of KVA12123, Kineta’s VISTA blocking immunotherapy, alone and with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. The presentation is scheduled for 9:00 A.M. – 7:00 P.M. Central Time at Exhibit Halls AB, George R. Brown Convention Center. Abstract titles are available on the SITC website, and posters will be accessible on Kineta’s website post-conference.

Kineta, Inc. (OTC Pink: KANT) announced that TuHURA Biosciences Inc has extended their exclusivity and right of first offer agreement for Kineta's VISTA blocking antibody KVA12123. This extension is part of the agreement entered in July 2024, allowing TuHURA to extend their rights for up to two 10-day periods, with Kineta receiving $150,000 for each extension.

Kineta reopened the Phase 1 clinical study in August 2024 and is currently enrolling patients with advanced solid tumor cancers. The company aims to complete enrollment by year-end 2024. KVA12123 has shown strong tumor growth inhibition in preclinical models and may be effective for various cancer types, including NSCLC, colorectal, renal cell carcinoma, head and neck, and ovarian cancer.

Kineta continues to explore strategic alternatives to maximize shareholder value, with more information expected later this year.

Kineta, a clinical-stage biotech firm, announced its transition from Nasdaq to the OTC Pink Open Market, trading under the ticker KANT as of September 19, 2024. This move follows Nasdaq's decision to delist Kineta due to non-compliance with the $1.00 minimum bid price and $2.5 million stockholders' equity requirements. Shareholders' investments remain secure and tradable. Kineta continues its focus on strategic alternatives and its KVA12123 Phase 1 study, which is open for new patient enrollment. Additionally, Kineta has an exclusivity agreement with TuHURA Biosciences, providing a $5 million nonrefundable payment and cooperation on the VISTA-101 Phase 1/2 trial.